Key result
miR-625-5p attenuated Ang II-induced cardiac hypertrophy by directly targeting and inhibiting the expression of STAT3 and CaMKII.
Why the study?
CaMKII is a key regulator of cardiac hypertrophy, but its regulatory mechanism remains largely unknown.
miR-625-5p acts as a novel negative regulator of cardiac hypertrophy by targeting STAT3 and CaMKII, offering a potential molecular mechanism and therapeutic target.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for miR-625-5p in hypertrophy; leaves open clinical translation from animal models.
Cardiac hypertrophy is an adaptive cardiac response to heart stress. Sustained cardiac hypertrophy indicates higher risk of heart failure. Ca2+/calmodulin-dependent protein kinase II (CaMKII) has been proved to be a key regulator of cardiac hypertrophy, but its mechanism remains largely unknown. Our study proposed to explore the regulatory mechanism of CaMKII in cardiac hypertrophy. We validated that CaMKII was upregulated in cardiac hypertrophy models in vivo and in vitro and that knockdown of CaMKII attenuated Ang II–induced cardiac hypertrophy in vitro. Furthermore, we demonstrated that signal transducer and activator of transcription 3 (STAT3) was highly expressed in cardiac hypertrophy and could stimulate the transactivation of CaMKII. Moreover, we predicted through TargetScan and confirmed that miR-625-5p targeted and inhibited STAT3 so as to reduce the expression of CaMKII. Interestingly, we also found that miR-625-5p directly targeted CaMKII and inhibited its expression. Rescue assays suggested that miR-625-5p attenuated Ang II–induced cardiac hypertrophy through CaMKII/STAT3. Consequently, this study elucidated that miR-625-5p inhibited cardiac hypertrophy through targeting STAT3 and CaMKII, suggesting miR-625-5p as a novel negative regulator of cardiac hypertrophy. Color images are available online.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2019) studied Cardiac hypertrophy. miR-625-5p was evaluated on Cardiac hypertrophy. miR-625-5p attenuated Ang II-induced cardiac hypertrophy by directly targeting and inhibiting the expression of STAT3 and CaMKII.
Synapse has enriched 10 related papers. Consider them for comparative context: